Zoetis Inc. $ZTS Stock Position Raised by Vantage Wealth

Vantage Wealth increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 20.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 130,555 shares of the company’s stock after acquiring an additional 22,085 shares during the quarter. Zoetis makes up approximately 3.6% of Vantage Wealth’s holdings, making the stock its 22nd biggest holding. Vantage Wealth’s holdings in Zoetis were worth $16,426,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Summit Place Financial Advisors LLC grew its holdings in shares of Zoetis by 0.4% during the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company’s stock valued at $2,834,000 after purchasing an additional 76 shares during the last quarter. First County Bank CT lifted its holdings in shares of Zoetis by 5.4% in the 3rd quarter. First County Bank CT now owns 1,535 shares of the company’s stock worth $225,000 after purchasing an additional 79 shares during the last quarter. CWA Asset Management Group LLC boosted its position in Zoetis by 1.1% during the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company’s stock valued at $1,059,000 after purchasing an additional 80 shares during the period. Balefire LLC grew its stake in Zoetis by 3.5% during the 3rd quarter. Balefire LLC now owns 2,463 shares of the company’s stock worth $360,000 after buying an additional 84 shares during the last quarter. Finally, Evergreen Capital Management LLC grew its stake in Zoetis by 3.3% during the 3rd quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock worth $394,000 after buying an additional 85 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have issued reports on ZTS. Morgan Stanley set a $160.00 target price on Zoetis in a research note on Thursday, December 18th. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. UBS Group set a $136.00 price objective on shares of Zoetis in a report on Thursday, January 29th. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday. Finally, Bank of America boosted their target price on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Price Performance

Shares of NYSE ZTS opened at $113.48 on Monday. Zoetis Inc. has a fifty-two week low of $113.29 and a fifty-two week high of $172.23. The firm’s 50-day simple moving average is $123.39 and its 200 day simple moving average is $129.03. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The stock has a market cap of $47.90 billion, a P/E ratio of 18.85, a P/E/G ratio of 1.73 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.